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Abstract
Introduction Signal transducer and activator of transcription 3
(Stat3) is constitutively tyrosine-phosphorylated in
approximately 50% of primary breast carcinomas. A number of
different mechanisms responsible for Stat3 activation, including
abnormal activation of receptor tyrosine kinases, Src, and Janus
kinases (Jaks), have been implicated in breast cancer.
Methods We examined six breast cancer-derived cell lines
expressing high or low levels of tyrosine-phosphorylated Stat3
(pStat3) as well as primary breast cancer specimens.
Results Inhibition of Src or EGFR (epidermal growth factor
receptor) tyrosine kinases had no effect on pStat3 levels,
whereas pan-Jak inhibitor P6 resulted in complete abrogation of
Stat3 phosphorylation and inhibition of growth. Jaks are required
for cytokine signaling, and the glycoprotein 130 (gp130)
receptor-associated Jaks are known mediators of Stat3
phosphorylation. Blockade of the gp130 receptor or
sequestration of the interleukin-6 (IL-6) ligand led to a decrease
of pStat3 levels. Conditioned media from those cell lines
expressing high levels of pStat3 contained IL-6 and were
capable of stimulating Stat3 phosphorylation. We examined IL-
6 levels in primary breast tumors and found a positive correlation
between pStat3 and IL-6 expression.
Conclusion In summary, a principal mechanism of Stat3
activation in breast cancer is through the IL-6/gp130/Jak
pathway.
Introduction
The Stat (signal transducer and activator of transcription) fam-
ily of proteins are transcription factors known for their role as
integrators of cytokine and growth factor receptor signaling
and are required for cell growth, survival, differentiation, and
motility [1,2]. Stat activation is dependent upon tyrosine phos-
phorylation, which induces dimerization via reciprocal phos-
photyrosine-SH2 (Src homology domain 2) interaction
between two Stat molecules. Activated Stats translocate to
the nucleus, where they bind to consensus promoter
sequences of target genes and activate their transcription [3].
In normal non-transformed cells, Stat tyrosine phosphorylation
is transient. However, in numerous cancer-derived cell lines
and in an ever-growing number of primary tumors, Stat pro-
teins (in particular, Stat3) are persistently tyrosine-phosphor-
ylated [4].
Stat3 is constitutively activated in more than 50% of primary
breast tumors and tumor-derived cell lines [5-17]. Clinical
studies demonstrated that elevated levels of tyrosine-phos-
phorylated Stat3 (pStat3) in patients with stage II breast
cancer correlated with an incomplete response to neo-adju-
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vant chemotherapy (a poor prognostic feature) [7]. The evi-
dence that activated Stat3 participates in a causal manner in
breast tumorigenesis is based on studies from cell lines
expressing high levels of pStat3. Inhibiting or removing Stat3
leads to increased apoptosis, chemosensitivity, and
decreased angiogenesis both in cell culture and in xenograft
models [5,6,10,13,14,18-22]. Furthermore, the expression of
a constitutively active form of Stat3 (Stat3C) into immortalized
human breast epithelial cells mediated de novo tumorigenesis,
demonstrating the sufficiency of this transcription factor in pro-
moting cellular transformation [16]. Stat3 activation can occur
through the actions of many autocrine and paracrine growth
factors (for example, interleukin-6 [IL-6], epidermal growth fac-
tor, platelet-derived growth factor, heregulin, vascular
endothelial growth factor, and hepatocyte growth factor) and
the Src non-receptor tyrosine kinase, leading to the prediction
that its phosphorylation in breast cancer would be through
these multiple, redundantly acting growth factors [6-
8,12,13,18,19,23-25]. Among these candidate cytokines, IL-
6, which activates Stat3 through the glycoprotein 130/Janus
kinase (gp130/Jak) pathway, is notable for its pleiotropic
tumor-promoting activities, including anti-apoptotic, pro-inva-
sive, and immune-stimulatory effects attributable to the activa-
tion of Stat3 target genes [26,27]. Furthermore, high IL-6
levels have been linked to a poor prognosis in patients with
advanced breast cancer, the pathogenesis of inflammatory
breast cancer, and resistance to chemotherapy [26]. Our
studies have revealed a prominent and non-redundant role for
IL-6 in driving Stat3 activation in breast cancer.
Materials and methods
Cell culture
MCF7, BT-474, MDA-MB-435, MDA-MB-468, MDA-MB-231,
and MCF10A cells were purchased from the American Type
Culture Collection (Manassas, VA, USA) and grown in Dul-
becco's modified Eagle's medium supplemented with penicil-
lin/streptomycin (Invitrogen Corporation, Carlsbad, CA, USA)
and 10% fetal bovine serum. MCF10A cells were cultured as
described previously [28]. The 4175 metastatic subline of
MDA-MB-231 cells was a gift from Joan Massague (Memorial
Sloan-Kettering Cancer Center [MSKCC], New York, NY,
USA) and was cultured as previously described [29]. Cell pro-
liferation was determined using an MTT (3- [4,5-dimethylthia-
zol-2-yl]-2,5-diphenyltetrazolium bromide) assay (as described
by the vendor) with a microplate reader (Sigma-Aldrich, St.
Louis, MO, USA).
Immunohistochemical assays
Multitissue blocks of formalin-fixed, paraffin-embedded breast
cancer tissue (containing three or four representative 0.6-mm
cores) were prepared using a tissue arrayer, and immunohis-
tochemistry (IHC) was performed as described [16,30]. Anti-
gen retrieval using citric acid (pH 6.0) at 97°C for 30 minutes
was followed by treatment with 3% H2O2. Phospho-Stat3
(Tyr-705) (Cell Signaling Technology, Inc., Danvers, MA, USA)
was used at 1:200. Anti-human IL-6 goat polyclonal antibody
(R&D Systems, Inc., Minneapolis, MN, USA) was used at a
1:100 dilution [31]. Anti-human estrogen receptor (ER) anti-
body (Immunotech, now part of Beckman Coulter, Fullerton,
CA, USA) anti-human progesterone receptor (PR) antibody
(BioGenex, San Ramon, CA, USA), and anti-Her2neu antibody
(CB11; Dako North America, Inc., Carpinteria, CA, USA) were
used at a 1:200 dilution. pStat3 positivity was defined as 3+,
2+, 1+, or 0 by IHC. Her2 positivity was defined as 3+ by IHC
or as 2+ by IHC with a gene amplification of 2.1 or greater
[30]. For ER and PR, samples were considered positive if
more than 10% of cell nuclei were immunoreactive. Scoring of
the tissue microarray was performed by two independent
observers (JFB and MB) with a high correlation between scor-
ers (p < 0.001) for both pStat3 and IL-6. For a tumor to be
considered positive for either pStat3 or IL-6, all four replicates
in the tissue array had to have a similar staining intensity; oth-
erwise, the tumor was excluded. Statistical analyses were per-
formed using STATVIEW (SAS Institute Inc., Cary, NC, USA).
The correlation between the scores of both scorers and the
relationship between that of pStat3 and IL-6, ER, PR, and
Her2neu were measured using the χ2 test.
Enzyme-linked immunosorbent assay
Cells were grown to approximately 50% to 85% confluence,
and conditioned media (CM) was analyzed for IL-6 by means
of an IL-6 enzyme-linked immunosorbent assay (ELISA) kit
(Cell Sciences, Inc., Canton, MA, USA) according to the man-
ufacturer's instructions.
Western blot and antibodies
Whole-cell, nuclear, and cytoplasmic extracts were prepared
as previously described [5]. Protein concentration was deter-
mined using the Bradford assay (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA), and Western blot analysis was carried
out by standard methods. Antibodies for Western blotting
included Stat3, pStat3, Src, and pSrc (Cell Signaling Technol-
ogy, Inc.). Phosphorylated Jak2 and Jak2 antibodies were
obtained from Calbiochem (San Diego, CA, USA) and Upstate
(now part of Millipore Corporation, Billerica, MA, USA),
respectively. Gp130-blocking antibody, BR-3, and IL-6-block-
ing antibody, 522, were obtained from Cell Sciences, Inc.
Leukemia inhibitory factor (LIF)-blocking and oncostatin M
(OSM)-blocking antibodies were purchased from R&D Sys-
tems, Inc.
Reagents
Tetracyclic pyridone 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz
[h]-imidaz [4,5-f]isoquinoline-7-one, P6, was synthesized by
author WB [37]. Gefitinib (ZD) was a gift from AstraZeneca
(London, UK) provided by Jackie She from the Anti-Tumor
Assessment Core Facility, MSKCC. Dasatinib (BMS-354825)
was synthesized by Darren Veach at MSKCC.Available online http://breast-cancer-research.com/content/9/3/R32
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Results
Stat3 is tyrosine-phosphorylated in approximately 50% 
of primary breast tumors
Persistently activated Stat3 has been shown to play an impor-
tant role in the pathogenesis of breast tumorigenesis based
primarily on studies in breast cancer-derived cell lines using
anti-sense, short interfering RNA and dominant negative Stat3
constructs and a variety of different drugs leading to Stat3
inhibition. The mechanisms of Stat3 activation have been pre-
sumed to involve multiple, redundantly acting growth factors
and activated tyrosine kinases, making inhibition of one of
these unlikely to lead to effective inhibition of Stat3 in breast
cancer. To explore these potential mechanisms, we evaluated
85 primary breast cancer specimens and examined nuclear
pStat3 levels by IHC. We determined that 46% expressed
high to moderate levels (3, 2+) of nuclear pStat3, 23% low
levels (+1), and 31% no detectable pStat3 (Figure 1). Breast
tumors are classified by expression of the nuclear hormone
receptors estrogen and progesterone as well as the receptor
tyrosine kinase Her2neu principally as a consequence of the
available therapeutics targeting these pathways (selective ER
modulators, aromatase inhibitors, trastuzumab, and laptinib).
We also examined ER, PR, and Her2neu levels by IHC, and no
correlation consistent with prior reports was observed
between high to moderate nuclear pStat3 and high ER, PR, or
Her2neu expression (Table 1) [7,11,17].
Stat3 is constitutively tyrosine-phosphorylated in breast 
cancer-derived cell lines
We examined the relative levels of pStat3 in an immortalized
breast epithelial cell line as well as five different breast cancer-
derived cell lines. MCF10A, MCF7, and BT474 cell lines had
low levels of pStat3, whereas MDA-MB-435, MDA-MB-468,
and MDA-MB-231 cell lines expressed higher levels of pStat3
(Figure 2) [10,12,13]. We also examined tyrosine-phosphor-
ylated Stat1 and found that only the MDA-MB-468 cells con-
tained low levels of pStat1 (data not shown).
Stat3 phosphorylation is blocked by Jak kinase 
inhibition but not Src or epidermal growth factor 
receptor blockade
A number of different tyrosine kinases, including the epidermal
growth factor receptor (EGFR) family of tyrosine kinases, Src,
and Jaks, have been described as mediating Stat3 phosphor-
Table 1
Immunohistochemical analysis of 85 primary breast tumors for pStat3, interleukin-6, estrogen receptor, progesterone receptor, and 
Her2neu
pStat3 0, 1+ (54%) pStat3 2, 3+ (46%) P value (Fisher)
Interleukin-6 (2, 3+) 11 32 0.001
Interleukin-6 (0, 1+) 34 5
Estrogen receptor-positive 21 25 0.20
Estrogen receptor-negative 24 14
Progesterone receptor-positive 16 18 1.0
Progesterone receptor-negative 29 19
Her2neu (2, 3+) 5 7 1.0
Her2neu (0, 1+) 30 25
The correlations between the relationship of pStat3 and interleukin-6, estrogen receptor, progesterone receptor, and Her2neu were measured 
using the χ2 test. 0 is no staining, 1+ is weak staining, 2+ is moderate staining and 3+ is strong staining for pStat3, tyrosine-phosphorylated signal 
transducer and activator of transcription 3 and IL-6.
Figure 1
Signal transducer and activator of transcription 3 (Stat3) phosphorylation in primary breast cancer Signal transducer and activator of transcription 3 (Stat3) phosphorylation in primary breast cancer. Tissue microarrays of primary breast tumors (85) 
were analyzed for nuclear tyrosine-phosphorylated Stat3 (pStat3) by immunohistochemical analysis. Ten percent expressed high levels (3+), 36% 
moderate levels (+2), 23% low levels (+1), and 31% no detectable pStat3 (0).Breast Cancer Research    Vol 9 No 3    Berishaj et al.
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ylation in both primary tumors and breast cancer-derived cell
lines [6,13,23,25,32]. Specifically, it has been demonstrated
that an inhibitor of Src kinase resulted in abrogation of pStat3
in the above-described cell lines and that a positive correlation
between pStat3 and pSrc existed in primary breast cancer
samples [6,13]. Similarly, an inhibitor of EGFR was shown to
inhibit Stat3 activation and it was shown that high EGFR was
positively correlated with Stat3 in breast cancer
[8,19,23,24,32]. The gold standard for Jak2 inhibition has
been the tyrphostin AG490 [33-35]. We recently compared
the sensitivity and specificity of AG490 to those of a novel
pan-Jak inhibitor (P6) on IL-6-dependent myeloma cells and
determined that P6 inhibited Jak/Stat3 signaling with higher
sensitivity and specificity than those of AG490, which indis-
criminately inhibited growth of cell lines, even those lacking
activated Jaks and Stats [35-37]. Here, we examined the
effects of a pan-Jak inhibitor (P6), a potent inhibitor of Src
(dasatinib, BMS), and an EGFR/Her2neu inhibitor (Gefitinib,
ZD) on pStat3 in these breast cancer-derived cell lines
[13,36,38-40]. We observed no effect of either the Src or
EGFR inhibitors on pStat3 in MDA-MB-435, MDA-MB-468,
and MDA-MB-231 cells, whereas the pan-Jak inhibitor led to a
profound decrease in pStat3 levels in all cell lines examined
(Figure 3). Low levels of pJak2 were observed in the MDA-MB-
468 cells, which were inhibited by P6 (Figure 3a). Decreased
pSrc and pEGFR was noted in the BMS- and ZD-treated cells,
respectively, demonstrating the efficacy of these drugs. Thus,
in contrast to other reports, we did not observe any effect of
either EGFR/Her2 or Src inhibition on Stat3 activation in
breast cancer-derived cell lines [13,19,32]. However, in all
cases, Jak inhibition resulted in complete abrogation of pStat3
levels. We examined the growth of MDA-MB-435, MDA-MB-
468, MCF-7, and MCF10A cells in the presence and absence
of P6 and observed growth inhibition by P6 of the cancer-
derived cell lines expressing high levels of pStat3 (Figure 3d).
Figure 2
Differential signal transducer and activator of transcription 3 (Stat3)  phosphorylation in breast cancer-derived cell lines Differential signal transducer and activator of transcription 3 (Stat3) 
phosphorylation in breast cancer-derived cell lines. Nuclear extracts 
(20 μg) isolated from MCF10A, MCF7, BT474, MDA-MB-435, MDA-
MB-MD-468, and MDA-MB-MD-231 cell lines were analyzed by West-
ern blotting with tyrosine-phosphorylated Stat3 (pStat3) and Stat3 
antibodies.
Figure 3
Signal transducer and activator of transcription 3 (Stat3) phosphorylation is mediated through Janus kinases (Jaks) but not epidermal growth factor  receptor (EGFR) or Src kinases Signal transducer and activator of transcription 3 (Stat3) phosphorylation is mediated through Janus kinases (Jaks) but not epidermal growth factor 
receptor (EGFR) or Src kinases. (a) Radioimmunoprecipitation assay (RIPA) extracts (50 μg) isolated from MDA-MB-468 cells treated for 4 hours 
with dimethyl sulfoxide (DMSO), P6 1 μM, BMS 50 nM, and ZD 2 μM were analyzed for pEGFR, total EGFR, tyrosine-phosphorylated Stat3 
(pStat3), Stat3, pSrc, Src, pJak2, and Jak2. (b) Nuclear extracts (20 μg) isolated from MDA-MB-435 cells (upper panels) and RIPA extracts (bottom 
panels) treated as in (a) and probed with the indicated antibodies. (c) Nuclear extracts (20 μg) isolated from MDA-MB-231 cells (upper panels) and 
RIPA extracts (bottom panels) treated as in (a) and probed with the indicated antibodies. (d) Ten thousand cells (MCF10A, MCF7, MDA-MB-468, 
and MDA-MB-435) were plated into a 96-well culture dish and treated with DMSO control or P6 (1 μM) for 48 hours, and proliferation was meas-
ured using an MTT (3- [4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay.Available online http://breast-cancer-research.com/content/9/3/R32
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Gp130 and IL-6 blockade inhibits Stat3 activation in 
breast cancer-derived cell lines
Jaks are obligate mediators of cytokine receptor signaling.
Among these candidate cytokines, IL-6, which activates Stat3
through the gp130/Jak pathway, is notable for its pleitrophic
tumor-promoting activities, including anti-apoptotic, pro-inva-
sive, and immune-stimulatory effects attributable to the activa-
tion of Stat3 target genes [26,27]. We hypothesized that Jaks
(Jak1, Jak2, and Tyk2) in association with the gp130 receptor
were the principal mediators of Stat3 activation in these cell
lines. Blockade of the gp130 receptor led to a decrease in
pStat3 levels in MDA-MB-435, MDA-MB-468, and MDA-MB-
231 cells (Figure 4). Sequestration of the IL-6 ligand using an
anti-human IL-6 antibody also led to a significant reduction in
pStat3 levels in MDA-MB-231, 4175, and MDA-MB-468 cell
lines (Figure 4 and data not shown). Recently, individual sin-
gle-cell-derived isolates subcloned from the breast cancer cell
line MDA-MB-231 were characterized as having distinct met-
astatic abilities and tissue tropisms [41]. Specifically, the
4175 subline metastasizes to the lung when injected into the
tail vein whereas the parental 231 line does not [41]. We
examined the relative levels of pStat3 in the parental 231 cells
and 4175 subline and determined that pStat3 levels were
higher in the highly metastatic 4175 line (Figure 4d). Blockade
of the gp130 receptor inhibited Stat3 phosphorylation in the
4175 subline as well as the parental 231 cell line (Figure 4d).
We confirmed in these cultured cells that autocrine production
of IL-6 is directly responsible for activating Stat3. CM from
MDA-MB-468, MDA-MB-231, and 4175 cell lines contained
high levels of IL-6 as measured by ELISA (942, 2,456, and
6,216 pg/ml, respectively). Furthermore, activation of Stat3 in
MCF10A cells elicited by CM from MDA-MB-468 cells could
be blocked by both the gp130-blocking antibody and the IL-6
sequestering antibody, but not by anti-OSM or anti-LIF anti-
bodies (Figure 4e). Similar results were obtained using CM
from MDA-MB-231 and 4175 cells (data not shown). These
data suggest that the mechanism of Stat3 activation in these
breast cancer-derived cell lines is through the IL-6 family of
cytokines, which are acting in an autocrine/paracrine manner.
High IL-6 and pStat3 levels positively correlate in primary 
breast cancer
To directly examine the singular importance of IL-6 as the acti-
vator of Stat3 in breast cancer, pStat3 levels and IL-6 levels
were compared by IHC analysis of our primary breast cancer
specimens (Figure 1). Eighty-two were evaluable for IL-6, and
52% of these expressed moderate to high levels of IL-6 (2, 3+)
whereas 48% expressed low levels of IL-6. Examples of both
high and low IL-6 by IHC are shown in Figure 5. A positive cor-
relation between (2, 3+) pStat3 and (2, 3+) IL-6 levels was
observed (p < 0.001) (Table 1).
Discussion
By using animals deficient for Stat3 in certain tissues or by
introducing dominant negative Stat3 constructs and anti-
sense and short hairpin RNA Stat3 molecules into cell lines,
Figure 4
Signal transducer and activator of transcription 3 (Stat3) activation is through the interleukin-6/glycoprotein 130/Janus kinase (IL-6/gp130/Jak)  pathway Signal transducer and activator of transcription 3 (Stat3) activation is through the interleukin-6/glycoprotein 130/Janus kinase (IL-6/gp130/Jak) 
pathway. (a) Nuclear extracts isolated from MDA-MB-468 (468) cells treated with immunoglobulin G (IgG) (10 μg/ml), P6 (1 μM), BR3 (10 μg/ml), 
and α-IL-6 (1 μg/ml) for 16 hours were analyzed for tyrosine-phosphorylated Stat3 (pStat3) and total Stat3 protein. (b) Nuclear extracts isolated 
from MDA-MB-231 (231) cells treated with IgG (10 μg/ml), P6 (1 μM), BR3 (10 μg/ml), and α-IL-6 (1 μg/ml) for 16 hours were analyzed for pStat3 
and total Stat3. (c) Nuclear extracts isolated from MDA-MB-435 (435) cells treated with IgG (10 μg/ml), P6 (1 μM), and BR3 (10 μg/ml) for 16 
hours were analyzed for pStat3 and total Stat3. (d) Nuclear extracts isolated from 4175 and 231 cells treated with IgG (10 μg/ml) and BR3 (10 μg/
ml) for 16 hours were analyzed for pStat3 and total Stat3. (e) Nuclear extracts isolated from MCF10A cells treated for 30 minutes with conditioned 
media (CM) from MDA-MB-468 cells after pretreatment for 4 hours with IgG control antibody, BR3 (5 μg/ml), α-IL-6 antibody (5 μg/ml), α-oncosta-
tin M (OSM) antibody (10 μg/ml), and α-leukemia inhibitory factor (LIF) antibody (10 μg/ml) were analyzed for pStat3 and total Stat3.Breast Cancer Research    Vol 9 No 3    Berishaj et al.
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many investigators have demonstrated a requirement for Stat3
in tumorigenesis [42]. Thus, inhibiting Stat3 activity or expres-
sion is likely to be an important therapeutic modality for a
number of malignancies, including breast cancer. Targeting
the Stat3 molecule directly is of significant interest, and
indeed several small molecules that appear to target the Stat3
SH2 domain or the DNA-binding capacity of Stat3 have been
developed [43-45]. It has been assumed that the kinases
responsible for Stat3 activation are many, and therefore target-
ing one kinase or receptor would not be of benefit for the treat-
ment of a variety of tumors.
Here, we examined the mechanisms of Stat3 phosphorylation
in breast cancer. We observed that high pStat3 levels in pri-
mary tumor specimens did not correlate with nuclear hormone
receptor status (ER or PR) nor overexpression of the Her2neu
receptor (Table 1). It has been suggested in murine models of
breast cancer that aberrant Her2neu signaling may mediate
Stat3 activation [22]. However, in primary human breast
tumors, no such relationship was observed [7,11,17]. We
examined pSrc and pEGFR levels by IHC in these tumor
specimens, but less than 3% of the samples had elevated
expression of these proteins, possibly for technical reasons as
these values appear to be too low compared to other reports
(data not shown) [7,8]. To examine the potential mechanisms
involved in mediating Stat3 phosphorylation, we examined
breast cancer-derived cell lines expressing high levels of
pStat3. Inhibition of EGFR and Src kinases did not have an
effect on pStat3, suggesting that these kinases are not direct
mediators of Stat3 phosphorylation in these breast cancer-
derived cell lines. Our data regarding Src inhibition differ from
those described by Garcia and colleagues [13] whereby treat-
ment of MDA-MB-468 cells with an Src inhibitor (PD180970)
resulted in inhibition of pStat3. Similarly, it was reported that
treatment of MDA-MB-231 cells w i t h  a n  E G F R  i n h i b i t o r
(AG1478) inhibited Stat3 activation [19]. In our study, we
used different inhibitors of both Src and EGFR at concentra-
tions previously described to potently inhibit both of these
kinases. The explanations for these discrepancies are not
clear, but differences in inhibitor selectivity and the length of
time for which cells are treated could explain our differing
observations. Interestingly, dasatinib treatment of both lung
and prostate cancer-derived cell lines did not affect pStat3
levels, suggesting that Src inhibition does not play a role in
mediating Stat3 activation in these cancer-derived cell lines
[38,39]. In contrast to EGFR and Src inhibition, a pan-Jak
inhibitor inhibited pJak2 and Stat3 phosphorylation (Figure 3).
Furthermore, treatment of the cell lines with an anti-gp130
antibody significantly inhibited Stat3 phosphorylation (Figure
4). Given the previously described association between the
EGFR family members and gp130 receptor, we attempted but
were unable to show any physical association between EGFR
and gp130 by immunoprecipitation experiments in MDA-MB-
468 cells (which express the highest levels of EGFR) (data not
shown) [19].
The cytokine receptor gp130 is the common signaling subunit
for the IL-6 family of cytokines. The gp130 receptor is ubiqui-
tously expressed in tissues and mediates numerous homeo-
static functions, including immune response, inflammation,
bone metabolism, and hematopoiesis [27]. IL-6, IL-11, OSM,
LIF, and ciliary neurotropic factor are among the IL-6 family
cytokines that use and require gp130 as a signaling subunit
[27]. We determined that IL-6 was the essential cytokine
mediating gp130 activation in MDA-MB-468 and MDA-MB-
231 cells and the 4175 subline (Figure 4). We did not observe
inhibition of pStat3 by the IL-6-blocking antibody in the MDA-
MB-435 cell line nor was IL-6, LIF, or OSM detected in the CM
from this cell line. We believe that IL-11 is responsible for
mediating Stat3 activation because IL-11 mRNA levels were
increased in this cell line compared to MDA-MB-468 cells
(data not shown). However, we have yet to confirm by immu-
nological means that IL-11 is mediating gp130 activation.
The data presented here suggest that the principal mediator of
Stat3 activation in breast cancer is through the IL-6 family of
cytokines activating the gp130/Jak signaling pathway. Stat3
activation through the gp130 receptor is regulated by both
positive effectors such as IL-6 and negative regulators, includ-
ing suppressor of cytokine signaling (SOCS) 1 and SOCS3,
which inhibit Jak activity [46]. SOCS1 and SOCS3 promoters
are frequently methylated in primary tumors and cancer-
derived cell lines, resulting in decreased expression of these
negative regulators of Jaks and leading to sustained Jak acti-
vation [47]. We hypothesize that even in the absence of IL-6
or IL-6 engagement with the gp130 receptor, Jaks may still be
Figure 5
Immunohisotchemical analaysis of primary breast cancer specimens for  interleukin-6 (IL-6) (upper panels) and tyrosine-phosphorylated signal  transducer and activator of transcription 3 (pStat3) (bottom panels) Immunohisotchemical analaysis of primary breast cancer specimens for 
interleukin-6 (IL-6) (upper panels) and tyrosine-phosphorylated signal 
transducer and activator of transcription 3 (pStat3) (bottom panels). 
Examples of high pStat3 and IL-6 (left panels) as well as low pStat3 
and IL-6 (right panels) are indicated.Available online http://breast-cancer-research.com/content/9/3/R32
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activated due to the lack of SOCS gene expression and can
only be fully inhibited with a Jak inhibitor.
To directly examine the singular importance of IL-6 as the acti-
vator of Stat3 in breast cancer, pStat3 levels and IL-6 levels
were compared by IHC analysis of 82 primary breast cancer
specimens and a significant positive correlation was observed
between high pStat3 and high IL-6 levels as determined by
IHC (p < 0.001). We also examined levels of gp130 and were
unable to obtain consistent immunohistochemical data (data
not shown).
Conclusion
We propose that the IL-6/gp130/Jak signaling pathway plays
a critical role in Stat3 activation in human breast cancer and
that blockade of this pathway may be an important therapeutic
modality in breast cancer.
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